Elevation of Donor-derived Cell-free DNA Before Biopsy-proven Rejection in Kidney Transplant

Abstract

These data indicate that dd-cfDNA is an early indicator of biopsy-proven rejection, especially ABMR, suggesting a greater role for dd-cfDNA in surveillance to identify patients at high risk of ongoing or future rejection, thus requiring closer monitoring, biopsy, or other management changes.